(CercleFinance.com) – Cellectis shares are sailing against the tide of the Parisian market on Tuesday morning following the publication of half-year results marked by a reduction in losses for the biopharmaceutical company.
Around 10:00 a.m., the stock rose by more than 3% while the SBF 120 oscillated around equilibrium.
Consolidated revenue and other operating income for the first six months of the year amounted to $5.6 million, compared to $6.5 million for the first six months of 2022.
The company, which specializes in allogeneic immunotherapy therapeutic products based on CAR-T cells, explains this decline by the disappearance of milestone payments received from the American Cytovia Therapeutics in 2022.
At the same time, its research and development (R&D) costs fell to 43.2 million dollars over the first six months of the year, against 52.2 million a year earlier.
In addition, its administrative and selling expenses fell to $8.9 million from $10.9 million for the first six months of 2022.
As a result, adjusted net loss attributable to Cellectis shareholders narrowed to $36.7 million for the half-year, compared to a loss of $45.5 million for the first six months of 2022.
As of June 30, 2023, Cellectis had $89 million in consolidated cash, cash equivalents and escrow accounts, compared to $95 million as of December 31, 2022.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about CELLECTIS in real time: